BridgeBio Pharma BBIO Non-Controlling Interests
Non-Controlling Interests at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:MinorityInterest.
The official record: BridgeBio Pharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about BridgeBio Pharma's non-controlling interests.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BridgeBio Pharma's non-controlling interests?
- BridgeBio Pharma (BBIO) reported non-controlling interests of $10.44M in Q1 2026.
- How has BridgeBio Pharma's non-controlling interests changed year-over-year?
- BridgeBio Pharma's non-controlling interests increased by 4.8% year-over-year, from $9.96M to $10.44M.
- What is the long-term trend for BridgeBio Pharma's non-controlling interests?
- Over 5 years (2020 to 2025), BridgeBio Pharma's non-controlling interests has grown at a -26.2% compound annual growth rate (CAGR), from $48.35M to $10.6M.
- What does non-controlling interests mean?
- The portion of a subsidiary's equity owned by outside parties rather than the parent company.
- How do you interpret non-controlling interests?
- An increase suggests the company has consolidated more entities where it does not hold 100% ownership, while a decrease may indicate buyouts of minority interests or divestitures.
- How does non-controlling interests compare across companies?
- Common in pharmaceutical companies with complex joint ventures or partially owned research subsidiaries; peers often report this as a distinct line item within equity.